Imugene Says Additional Patient in BTKi Group of Azer-Cel Phase 1b Study Achieves Complete Response, Shares Surge 26%
MT Newswires Live
Jul 01
Imugene (ASX:IMU) said additional patient data from the concurrent Bruton's tyrosine-protein inhibitor (BTKi) group of its azer-cel therapy candidate phase 1b study showed a complete response, according to a Friday Australian bourse filing.
Azer-cel is an off-the-shelf allogeneic CAR T cell therapy targeting the CD19 protein to treat blood cancers.
The mantle cell lymphoma (MCL) patient was the first one treated in the study and had previously failed BTKi therapy. The patient achieved a complete response at the day 28 assessment.
To date, four patients have been dosed in the concurrent BTKi group, and two of these patients are evaluable, both achieving a complete response.
Its shares surged 26% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.